RU2650118C2 - Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться - Google Patents

Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться Download PDF

Info

Publication number
RU2650118C2
RU2650118C2 RU2016105581A RU2016105581A RU2650118C2 RU 2650118 C2 RU2650118 C2 RU 2650118C2 RU 2016105581 A RU2016105581 A RU 2016105581A RU 2016105581 A RU2016105581 A RU 2016105581A RU 2650118 C2 RU2650118 C2 RU 2650118C2
Authority
RU
Russia
Prior art keywords
alkyl
cough
compound
formula
haloc
Prior art date
Application number
RU2016105581A
Other languages
English (en)
Russian (ru)
Other versions
RU2016105581A (ru
Inventor
Энтони П. ФОРД
Брюс Дж. МККАРТИ
Original Assignee
Афферент Фармасьютикалз Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52480919&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2650118(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Афферент Фармасьютикалз Инк. filed Critical Афферент Фармасьютикалз Инк.
Publication of RU2016105581A publication Critical patent/RU2016105581A/ru
Application granted granted Critical
Publication of RU2650118C2 publication Critical patent/RU2650118C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2016105581A 2013-08-23 2014-08-22 Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться RU2650118C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361869174P 2013-08-23 2013-08-23
US61/869,174 2013-08-23
PCT/US2014/052389 WO2015027212A1 (en) 2013-08-23 2014-08-22 Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough

Publications (2)

Publication Number Publication Date
RU2016105581A RU2016105581A (ru) 2017-09-28
RU2650118C2 true RU2650118C2 (ru) 2018-04-09

Family

ID=52480919

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016105581A RU2650118C2 (ru) 2013-08-23 2014-08-22 Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться

Country Status (20)

Country Link
US (3) US9284279B2 (enExample)
EP (2) EP3865134A1 (enExample)
JP (3) JP6546592B2 (enExample)
KR (1) KR102196885B1 (enExample)
CN (1) CN105682659B (enExample)
AU (1) AU2014308606B2 (enExample)
CA (1) CA2921395C (enExample)
CL (3) CL2016000400A1 (enExample)
CR (1) CR20160093A (enExample)
IL (1) IL244131B (enExample)
MX (1) MX367657B (enExample)
MY (1) MY195728A (enExample)
NI (1) NI201600029A (enExample)
NZ (1) NZ716977A (enExample)
PE (1) PE20160431A1 (enExample)
PH (1) PH12016500357A1 (enExample)
RU (1) RU2650118C2 (enExample)
SG (1) SG11201601145RA (enExample)
UA (1) UA118851C2 (enExample)
WO (1) WO2015027212A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2921395C (en) * 2013-08-23 2022-04-26 Afferent Pharmaceuticals Inc. Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
AU2015213681B2 (en) 2014-02-10 2020-03-12 Respivant Sciences Gmbh Mast cell stabilizers for lung disease treatment
WO2015120389A1 (en) 2014-02-10 2015-08-13 Patara Pharma, LLC Mast cell stabilizers treatment for systemic disorders
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP4215182A1 (en) * 2015-09-29 2023-07-26 Afferent Pharmaceuticals Inc. Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US9907795B2 (en) * 2016-01-08 2018-03-06 Nerre Therapeutics Limited Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents
US10662162B2 (en) * 2016-03-25 2020-05-26 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
CA3035528A1 (en) 2016-08-31 2018-03-08 Respivant Sciences Gmbh Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
CA3037746A1 (en) 2016-10-07 2018-04-12 Respivant Sciences Gmbh Cromolyn compositions for treatment of pulmonary fibrosis
EP3554504B1 (en) * 2016-12-15 2022-10-26 Afferent Pharmaceuticals Inc. Substituted pyrazole-pyrimidines, variants thereof, and uses thereof
US10676444B2 (en) * 2016-12-20 2020-06-09 Afferent Pharmaceuticals, Inc. Crystalline salts and polymorphs of a P2X3 antagonist
US10111883B1 (en) * 2017-09-18 2018-10-30 Bellus Health Cough Inc. Selective P2X3 modulators
CN108904507A (zh) * 2018-02-11 2018-11-30 赖英杰 P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用
CN112004551A (zh) 2018-03-15 2020-11-27 丹米尔治疗有限责任公司 3”,5”-二烷氧基苯甲酰基-3’-氨基-3’-脱氧腺苷-5’-三磷酸及其药物用途
JP7502997B6 (ja) * 2018-04-23 2024-07-12 メルク・シャープ・アンド・ドーム・エルエルシー フェノキシジアミノピリミジン化合物の新規な合成方法
BR112020022340A2 (pt) 2018-05-15 2021-02-02 Bayer Aktiengesellschaft benzamidas substituídas por 1,3-tiazol-2-il para o tratamento de doenças associadas com sensibilização de fibras nervosas
JOP20200286A1 (ar) * 2018-05-15 2020-11-09 Bayer Ag بنزاميدات مستبدلة بـ 1 ، 3-ثيازول-2-يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية
EP3826635A4 (en) 2018-07-23 2022-04-27 Trevi Therapeutics, Inc. TREATMENT OF CHRONIC COUGH, SHORTNESS OF BREATH AND DYSPNEA
CN113559104A (zh) * 2018-10-05 2021-10-29 盐野义制药株式会社 慢性咳嗽治疗用药物
CN113727716A (zh) 2019-02-25 2021-11-30 贝卢斯医疗咳嗽病公司 采用p2x3调节剂的治疗
AU2020266699B2 (en) 2019-04-30 2025-12-18 Beijing Tide Pharmaceutical Co., Ltd. Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof
MX2021013338A (es) * 2019-04-30 2022-01-24 Beijing Tide Pharmaceutical Co Ltd Método para tratar la tos usando un compuesto de diaminopirimidina.
AU2020348089B2 (en) 2019-09-19 2025-12-18 Shionogi & Co., Ltd. Crystal of 1,3,5-triazine derivative or solvate thereof and method for producing same
EP4087569A4 (en) 2020-01-10 2024-01-24 Trevi Therapeutics, Inc. METHODS OF ADMINISTRATION OF NALBUPHINE
CN111635368B (zh) * 2020-06-12 2021-06-29 东莞市东阳光仿制药研发有限公司 一种胺化合物的制备方法
CN120019423A (zh) 2022-10-12 2025-05-16 软银集团股份有限公司 信息处理系统、信息处理装置、控制装置及程序

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060029548A1 (en) * 2004-07-22 2006-02-09 Amir Pelleg Methods of diagnosing, monitoring and treating pulmonary diseases
US20070049758A1 (en) * 2005-09-01 2007-03-01 Roche Palo Alto Llc Diaminopyrimidines as P2X3 and P2X2/3 modulators
US20080086004A1 (en) * 2006-10-04 2008-04-10 Roche Palo Alto Llc Process for synthesis of phenoxy diaminopyrimidine derivatives
US20080207655A1 (en) * 2007-02-28 2008-08-28 Roche Palo Alto Llc Diaminopyrimidines as P2X3 and P2X2/3 modulators
RU2422441C2 (ru) * 2004-03-05 2011-06-27 Ф.Хоффманн-Ля Рош Аг Диаминопиримидины в качестве антагонистов рецепторов р2х3
US20120122859A1 (en) * 2005-09-01 2012-05-17 Roche Palo Alto Llc. Methods of using diaminopyrimidine as p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007025901A1 (en) 2005-09-01 2007-03-08 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 modulators
JP4820873B2 (ja) * 2005-09-01 2011-11-24 エフ．ホフマン−ラ ロシュ アーゲー アリールオキシジアミノピリミジンの合成方法
US9550763B2 (en) * 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
CA2921395C (en) 2013-08-23 2022-04-26 Afferent Pharmaceuticals Inc. Diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
US9222282B2 (en) * 2013-10-11 2015-12-29 Nexkey, Inc. Energy efficient multi-stable lock cylinder

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2422441C2 (ru) * 2004-03-05 2011-06-27 Ф.Хоффманн-Ля Рош Аг Диаминопиримидины в качестве антагонистов рецепторов р2х3
US20060029548A1 (en) * 2004-07-22 2006-02-09 Amir Pelleg Methods of diagnosing, monitoring and treating pulmonary diseases
US20070049758A1 (en) * 2005-09-01 2007-03-01 Roche Palo Alto Llc Diaminopyrimidines as P2X3 and P2X2/3 modulators
US20120122859A1 (en) * 2005-09-01 2012-05-17 Roche Palo Alto Llc. Methods of using diaminopyrimidine as p2x3 and p2x2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases
US20080086004A1 (en) * 2006-10-04 2008-04-10 Roche Palo Alto Llc Process for synthesis of phenoxy diaminopyrimidine derivatives
US20080207655A1 (en) * 2007-02-28 2008-08-28 Roche Palo Alto Llc Diaminopyrimidines as P2X3 and P2X2/3 modulators

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Carter, David S. et al., Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain. Bioorganic & Medicinal Chemistry Letters, 2009, 19(6), 1628-1631 (English). *

Also Published As

Publication number Publication date
WO2015027212A1 (en) 2015-02-26
CA2921395C (en) 2022-04-26
US20150057299A1 (en) 2015-02-26
CN105682659B (zh) 2019-12-10
US10206922B2 (en) 2019-02-19
JP7423725B2 (ja) 2024-01-29
MX2016002289A (es) 2016-09-06
US20160263112A1 (en) 2016-09-15
EP3035932A4 (en) 2017-01-04
CL2018002138A1 (es) 2018-10-05
EP3035932A1 (en) 2016-06-29
US20170326142A1 (en) 2017-11-16
CL2018002137A1 (es) 2018-10-05
UA118851C2 (uk) 2019-03-25
KR102196885B1 (ko) 2020-12-30
CN105682659A (zh) 2016-06-15
CL2016000400A1 (es) 2017-01-20
JP2019112459A (ja) 2019-07-11
IL244131A0 (en) 2016-04-21
JP2023002662A (ja) 2023-01-10
PE20160431A1 (es) 2016-06-02
US9724346B2 (en) 2017-08-08
EP3865134A1 (en) 2021-08-18
JP2016528301A (ja) 2016-09-15
JP6546592B2 (ja) 2019-07-17
RU2016105581A (ru) 2017-09-28
IL244131B (en) 2019-06-30
CA2921395A1 (en) 2015-02-26
JP7210348B2 (ja) 2023-01-23
MY195728A (en) 2023-02-07
AU2014308606A1 (en) 2016-03-10
KR20160052581A (ko) 2016-05-12
CR20160093A (es) 2016-08-26
NZ716977A (en) 2017-09-29
SG11201601145RA (en) 2016-03-30
MX367657B (es) 2019-08-30
PH12016500357A1 (en) 2016-05-16
US9284279B2 (en) 2016-03-15
NI201600029A (es) 2017-09-22
HK1222126A1 (zh) 2017-06-23
AU2014308606B2 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
RU2650118C2 (ru) Способ лечения острого, хронического и подострого кашля и непреодолимого желания откашляться
US20240285620A1 (en) Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
NO339497B1 (no) Diaminopyrimidiner, farmasøytiske preparater omfattende slike samt anvendelse av slike for behandling av sykdom
US10543211B2 (en) Methods and compositions for treating diseases and conditions
HK40095851A (en) Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
HK1222126B (zh) 用於治疗急性、亚急性或慢性咳嗽的二氨基嘧啶p2x3和p2x2/3受体调节剂